Department of Pharmacology, College of Pharmacy, University of Kufa, Kufa, Iraq.
Department of Clinical Laboratory Science, College of Pharmacy, University of Kufa, Kufa, Iraq.
Arch Razi Inst. 2022 Feb 28;77(1):449-459. doi: 10.22092/ARI.2021.356682.1894. eCollection 2022 Feb.
Cigarette smoking is a risk factor associated with different diseases, claiming millions of lives annually. Smoking status has been studied for a long time and proved to be a major cause of smokers' decreased immunity. In the present pandemic COVID-19 disease, there was an unclear belief about the effect of smoking on patients with COVID-19. Therefore, the current cross-sectional study aimed to evaluate the effect of cigarette smoking on the sequelae of COVID-19. This cross-sectional study involved 200 COVID-19 patients (114 males and 86 females) aged 13-77 years. A number of 87 patients were smokers, and the rest of them were non-smokers. All patients underwent a comprehensive laboratory assessment and diagnosis by full medical history by the physicians. The results indicated a significant difference (<0.001) between smokers and non-smokers in terms of hypertension, anticoagulant, steroid therapy, pulmonary lesion, oxygen saturation, and duration of disease. As an overall conclusion, it can be stated that COVID-19 is less severe in smokers and they require less intensive treatment.
吸烟是与多种疾病相关的风险因素,每年导致数百万人死亡。吸烟状况已经研究了很长时间,事实证明它是导致吸烟者免疫力下降的主要原因。在当前的 COVID-19 大流行中,人们对于吸烟对 COVID-19 患者的影响存在一种模糊的信念。因此,目前的这项横断面研究旨在评估吸烟对 COVID-19 后遗症的影响。这项横断面研究纳入了 200 名 COVID-19 患者(男性 114 名,女性 86 名),年龄在 13-77 岁之间。87 名患者为吸烟者,其余为非吸烟者。所有患者均接受了全面的实验室评估和由医生通过完整病史进行的诊断。结果表明,在高血压、抗凝剂、类固醇治疗、肺部病变、血氧饱和度和疾病持续时间方面,吸烟者和非吸烟者之间存在显著差异(<0.001)。总的来说,可以说吸烟者的 COVID-19 病情较轻,他们需要的治疗强度较低。